To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Merck to buy VC-backed VelosBio for $2.75bn
Merck has agreed to acquire VelosBio Inc, a portfolio company of Pappas Capital, for $2.75 billion in cash.
